[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 7 of about 7
1. Bijman MN, Hermelink CA, van Berkel MP, Laan AC, Janmaat ML, Peters GJ, Boven E: Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels. Biochem Pharmacol; 2008 Jan 15;75(2):427-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels.
  • We determined whether continuous exposure to celecoxib would increase the antiproliferative effects of a 1-h treatment with docetaxel or cisplatin in four human ovarian cancer cell lines.
  • COX-2 protein could not be detected in these cell lines, because of which three COX-2 positive human colon cancer cell lines were included.
  • Multiple drug effect analysis demonstrated additive to borderline antagonistic effects of celecoxib combined with docetaxel.
  • Combination indices with values of 1.4-2.5 in all cancer cell lines indicated antagonism between celecoxib and cisplatin regardless whether celecoxib preceded cisplatin for 3h, was added simultaneously or immediately after cisplatin.
  • Apoptotic features measured in COX-2-negative H134 ovarian cancer cells and COX-2-positive WiDr colon cancer cells, such as the activation of caspase-3 and the number of cells in sub-G0 of the cell cycle, induced by docetaxel were increased in the presence of celecoxib, but were abrogated upon addition of celecoxib to cisplatin.
  • Drugs did not affect p-Akt.
  • Taken together, our data demonstrate clear antagonistic effects when celecoxib is given concurrently with cisplatin, which is independent of COX-2 expression levels.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cisplatin / pharmacology. Colonic Neoplasms / drug therapy. Cyclooxygenase 2 / physiology. Ovarian Neoplasms / drug therapy. Pyrazoles / pharmacology. Sulfonamides / pharmacology. Taxoids / pharmacology
  • [MeSH-minor] Apoptosis / drug effects. Celecoxib. Cell Division / drug effects. Cell Line, Tumor. Cyclin-Dependent Kinase Inhibitor p21 / biosynthesis. DNA Adducts / analysis. Drug Interactions. Extracellular Signal-Regulated MAP Kinases / metabolism. Female. G2 Phase / drug effects. Humans

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CELECOXIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17936723.001).
  • [ISSN] 0006-2952
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA Adducts; 0 / Pyrazoles; 0 / Sulfonamides; 0 / Taxoids; 15H5577CQD / docetaxel; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; JCX84Q7J1L / Celecoxib; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, Modesitt SC, Lu KH, Geisler JP, Higgins RV, Magtibay PM, Cohn DE, Powell MA, Chu C, Stehman FB, van Nagell J: Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol; 2002 Oct;87(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy.
  • OBJECTIVES: The purpose of this study was to determine the recurrence rate, survival, and pregnancy outcome in patients with Stage IA and Stage IC invasive epithelial ovarian cancer treated with unilateral adnexectomy.
  • METHODS: A multi-institutional retrospective investigation was undertaken to identify patients with Stage IA and IC epithelial ovarian cancer who were treated with fertility-sparing surgery.
  • All patients with ovarian tumors of borderline malignancy were excluded.
  • Long-term follow-up was obtained through tumor registries and telephone interviews.
  • The time and sites of tumor recurrence, patient survival, and pregnancy outcomes were recorded for every patient.
  • RESULTS: Fifty two patients with Stage I epithelial ovarian cancer treated from 1965 to 2000 at 8 participating institutions were identified.
  • Cell type was distributed as follows: mucinous, 25; serous, 10; endometrioid, 10; clear cell, 5; and mixed, 2.
  • Patients received the following chemotherapeutic agents: cisplatin/taxol or carboplatin/taxol, 11; melphalan, 5; cisplatin and cyclophosphamide, 3; and single-agent cisplatin, 1.
  • Five patients developed tumor recurrence 8-78 months after initial surgery.
  • CONCLUSION: The long-term survival of patients with Stage IA and IC epithelial ovarian cancer treated with unilateral adnexectomy is excellent.
  • Fertility-sparing surgery should be considered as a treatment option in women with Stage I epithelial ovarian cancer who desire further childbearing.
  • [MeSH-major] Fertility. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Epithelial Cells / pathology. Female. Humans. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Ovariectomy / methods. Pregnancy. Pregnancy Complications, Neoplastic. Pregnancy Outcome. Retrospective Studies. Survival Rate. Treatment Outcome


3. Rosen DG, Yang G, Bast RC Jr, Liu J: Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer. Methods Enzymol; 2006;407:660-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer.
  • Mutations in K-ras or its downstream mediator BRAF have been detected in about two thirds of low-grade serous carcinomas and borderline serous tumors; mutations in K-ras are also often present in benign and invasive mucinous ovarian cancers.
  • Although the oncogenic allele H-ras(V12) is present in only approximately 6% of ovarian cancers, physiologically activated H-ras protein is commonly detected in human ovarian cancer, presumably because of an increase in upstream signals from tyrosine kinase growth factor receptors such as Her-2/neu, despite the lack of a Ras mutation.
  • The mechanisms by which ras oncogenes transform human epithelial cells are not clear.
  • The methods described here are what we use to culture human ovarian surface epithelial cells, to immortalize those cells, and to transform the immortalized cells with oncogenic H-ras or K-ras.
  • These Ras-transformed human ovarian surface epithelial cells form tumors in nude mice and recapitulate many features of human ovarian cancer, thus providing an excellent model system for studying the initiation and progression of human ovarian cancer.
  • [MeSH-major] Cell Transformation, Neoplastic. Oncogene Protein p21(ras) / pharmacology. Ovarian Neoplasms / physiopathology. Ovary / cytology
  • [MeSH-minor] Animals. Antigens, Viral, Tumor / pharmacology. Cells, Cultured. Epithelial Cells / drug effects. Female. Humans. Immunohistochemistry. Mice. Mice, Nude. Simian virus 40 / immunology. Telomerase / pharmacology. Transfection


Advertisement
4. Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP: In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol; 2004 Jan;92(1):160-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.
  • OBJECTIVES: To determine whether there is a relationship between histologic subtype of epithelial ovarian cancer and chemoresistance, we evaluated ovarian carcinomas of six histologic subtypes and correlated histology with in vitro drug response.
  • METHODS: In vitro drug response profiles for different histologic subsets of epithelial ovarian carcinomas exposed to standard relevant chemotherapy agents were determined in the Extreme Drug Resistance assay (EDR).
  • RESULTS: Of 5195 referred serial cases of epithelial ovarian cancer, there were 2660 papillary serous, 303 endometrioid, 142 mucinous, 102 clear cell, 952 undifferentiated carcinomas, and 42 tumors of low malignant potential.
  • For the samples as a whole, the incidences of extreme drug resistance to the tested chemotherapeutic agents were cisplatin 10%, carboplatin 16%, cyclophosphamide 16%, doxorubicin 40%, gemcitabine 21%, paclitaxel 22%, and topotecan 13%.
  • Clear cell and undifferentiated tumors had the lowest rates of EDR to paclitaxel (13% and 18%) and cyclophosphamide (7% and 11%), while borderline tumors showed high rates of EDR to these agents (52% and 63%, respectively).
  • As compared to all other subtypes, clear cell carcinomas had significantly higher Her-2 neu expression (19%).
  • Relative to papillary serous carcinomas, borderline tumors exhibited significantly lower rates of mP53 expression (60% vs.17%).
  • CONCLUSIONS: We found significant differences in the frequencies of extreme drug resistance to chemotherapeutic agents and biomarker expression among histologic subtypes of epithelial ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Drug Resistance, Multiple. Ovarian Neoplasms / classification
  • [MeSH-minor] Drug Resistance, Neoplasm. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Receptor, Epidermal Growth Factor / biosynthesis. Receptor, ErbB-2 / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis


5. Kato N, Sasou S, Teshima S, Motoyama T: Overexpression of laminin-5 gamma2 chain in clear cell carcinoma of the ovary. Virchows Arch; 2007 Mar;450(3):273-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of laminin-5 gamma2 chain in clear cell carcinoma of the ovary.
  • One of the characteristic microscopic features of ovarian clear cell carcinoma (CCC) is the densely hyaline basement membrane material expanding the stroma.
  • The biological significance of this material, however, has remained unclear.
  • Recent studies have shown that laminin-5 (LN-5), a major component of the epithelial basement membrane, plays a more active role in cell migration or tumor invasion.
  • In the present study, 20 CCCs and 5 borderline clear cell tumors were examined for LN-5 expression immunohistochemically, using an antibody against LN-5 gamma2 chain.
  • All of the 20 CCCs showed a focal or diffuse immunoreactivity with the LN-5 gamma2 chain in the tumor stroma; whereas, borderline clear cell tumors rarely showed a stromal immunoreactivity.
  • In vitro, CCC cell lines showed a significant increase in cell migration over excessive LN-5, and the migration was blocked by an antibody against integrin alpha3.
  • These results indicate that an interaction between CCC cells and extracellularly accumulated LN-5 is responsible for cell migration and the subsequent stromal invasion of CCC.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Laminin / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Antibodies, Blocking / pharmacology. Biomarkers, Tumor / metabolism. Cell Line, Tumor. Cell Movement / drug effects. Cytoplasm / metabolism. Cytoplasm / pathology. Female. Humans. Integrin alpha3 / immunology. Neoplasm Invasiveness. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 1991 Aug;114(3):567-76 [1860885.001]
  • [Cites] Exp Cell Res. 2004 Jul 15;297(2):508-20 [15212952.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5596-601 [10554040.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):4132-9 [7664291.001]
  • [Cites] Hum Pathol. 2005 May;36(5):522-30 [15948119.001]
  • [Cites] J Cell Biol. 1984 Apr;98(4):1474-80 [6715409.001]
  • [Cites] J Biol Chem. 2000 Oct 13;275(41):31896-907 [10926936.001]
  • [Cites] J Cell Biochem. 2004 Jul 1;92(4):701-14 [15211568.001]
  • [Cites] Int J Gynaecol Obstet. 2000 Aug;70(2):209-62 [11041682.001]
  • [Cites] Cell. 1991 May 17;65(4):599-610 [2032285.001]
  • [Cites] Science. 1997 Jul 11;277(5323):225-8 [9211848.001]
  • [Cites] J Cell Biochem. 2003 Feb 15;88(3):506-20 [12532327.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2315-21 [10357399.001]
  • [Cites] Cancer Sci. 2006 Feb;97(2):91-8 [16441418.001]
  • [Cites] J Cell Biol. 2000 Feb 7;148(3):615-24 [10662785.001]
  • [Cites] J Histochem Cytochem. 2005 Oct;53(10):1293-300 [15923364.001]
  • [Cites] Int J Cancer. 1998 Mar 30;76(1):63-72 [9533763.001]
  • [Cites] Int J Gynecol Pathol. 1999 Jan;18(1):52-7 [9891241.001]
  • [Cites] Gynecol Oncol. 1990 Jul;38(1):37-45 [2354825.001]
  • [Cites] J Pathol. 1996 Nov;180(3):290-4 [8958807.001]
  • (PMID = 17235566.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Blocking; 0 / Biomarkers, Tumor; 0 / Integrin alpha3; 0 / LAMC2 protein, human; 0 / Laminin
  •  go-up   go-down


6. Fujiwara K, Sakuragi N, Suzuki S, Yoshida N, Maehata K, Nishiya M, Koshida T, Sawai H, Aotani E, Kohno I: First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol; 2003 Sep;90(3):637-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up.
  • OBJECTIVE: Currently, no long-term follow-up data are available on intraperitoneal (IP) carboplatin-based chemotherapy for ovarian carcinoma.
  • In this study we evaluated retrospectively the survival and recurrence of a retrospective cohort of patients with epithelial ovarian cancer treated with first-line IP carboplatin-based therapy.
  • METHODS: Records were reviewed of 174 patients with epithelial ovarian cancer who received IP carboplatin-based therapy between 1990 and 2000.
  • All patients underwent surgical staging, and implantable port systems were placed regardless of residual tumor size.
  • The pathological slides were submitted and reviewed, and then nine patients were excluded because of borderline malignancies (n = 8), and wrong histology (n = 1).
  • Tumor grade was determined by the Universal grading system.
  • The distribution by stage and histology was as follows: high risk (grade 2/3, clear cell, capsule rupture) stage I, 54; II, 21; III, 72; IV, 18; and serous, 75; clear cell, 30; mucinous, 27; endometrioid, 20; others, 13.
  • The median survival for optimal and suboptimal stage III/IV patients was 51 months and 34 months, respectively.
  • The median survival of patients with stage III/IV disease was 51 months with carboplatin doses of 400 mg/m(2) or more, but it was only 25 months with carboplatin doses smaller than 400 mg/m(2).
  • Poor prognostic factors, determined by Cox regression multivariate analysis, were clear cell histology (P < 0.001) and a carboplatin dose smaller than 400 mg/m(2) (P = 0.002).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carboplatin / administration & dosage. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Infusion Pumps, Implantable. Infusions, Parenteral. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Retrospective Studies. Second-Look Surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Gynecol Oncol. 2003 Dec;91(3):662
  • (PMID = 13678738.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


7. Hua K, Feng W, Cao Q, Zhou X, Lu X, Feng Y: Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer. Int J Oncol; 2008 Nov;33(5):959-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer.
  • Estrogen and progestin are involved in ovarian carcinogenesis.
  • Change in nm23-H1 expression and the PIK3/AKT pathway are involved in carcinogenesis, development, invasion and metastasis of ovarian cancers.
  • Therefore, it is critical to understand the signaling pathways that regulate hormone-induced cell migration and invasion in ovarian cancer.
  • We investigated nm23-H1, AKT and pAKT expression by using immunohistochemical staining in ovarian clear cell adenocarcinoma, ovarian benign, borderline and malignant serous tumors and analyzed their relationship with prognostic factors.
  • Using ES-2 and SKOV-3 ovarian cancer cell lines, we studied the modulation of estrogen and progestin on cell migration and invasion as well as their effect on AKT, pAKT and nm23-H1 expression.
  • Furthermore, the signaling pathways were examined using pharmacological inhibitors (LY294002 and PD98059) or AKT siRNA combined with estrogen or progestin in the two cell lines.
  • Weak nm23-H1 and high AKT and pAKT expression was observed in ovarian serous adeno-carcinoma and ovarian clear cell adenocarcinoma.
  • Our data demonstrated that the expression of nm23-H1 was negatively correlated with tumor stage and grade and lymph node metastasis, whereas the expression of AKT/pAKT was positively correlated with these clinic factors.
  • Estrogen up-regulated pAKT expression and reduced nm23-H1 expression, which ultimately resulted in increased cell migration and invasion.
  • In contrast, progestin reduced pAKT expression and increased nm23-H1 expression, which inhibited cell migration.
  • Our data suggest that AKT and pAKT are unfavorable prognostic factors for ovarian serous adenocarcinoma and clear cell carcinomas whereas nm23-H1 expression predicates favorable patient prognosis.
  • Estrogen down-regulates nm23-H1 expression and promotes cell migration and invasion by activating the PIK3/AKT pathway.
  • [MeSH-major] Adenocarcinoma / enzymology. Antineoplastic Agents, Hormonal / pharmacology. Cystadenoma, Serous / enzymology. Estrogens / metabolism. Ovarian Neoplasms / enzymology. Phosphatidylinositol 3-Kinases / metabolism. Progestins / pharmacology. Proto-Oncogene Proteins c-akt / metabolism
  • [MeSH-minor] Cell Line, Tumor. Cell Movement. Dose-Response Relationship, Drug. Female. Humans. Medroxyprogesterone Acetate / pharmacology. Middle Aged. NM23 Nucleoside Diphosphate Kinases / metabolism. Neoplasm Metastasis. Neoplasm Staging. Phosphorylation. Prognosis. Protein Kinase Inhibitors / pharmacology. RNA Interference. RNA, Small Interfering / metabolism. Signal Transduction / drug effects. Time Factors

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949358.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogens; 0 / NM23 Nucleoside Diphosphate Kinases; 0 / Progestins; 0 / Protein Kinase Inhibitors; 0 / RNA, Small Interfering; C2QI4IOI2G / Medroxyprogesterone Acetate; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.4.6 / NME1 protein, human
  •  go-up   go-down






Advertisement